Alembic Pharmaceuticals Ltd reported a robust 29% increase in consolidated net profit to ₹202.7 crore in the fourth quarter ended March 31, compared to ₹156.89 crore in the corresponding period of the previous fiscal year. According to the company's regulatory filing, consolidated revenue from operations grew to ₹1,847.72 crore from ₹1,769.64 crore in the year-ago period. The strong performance was driven by revenue gains across segments and the company's strategic entry into the US branded market. Sequentially, profit surged from ₹133 crore in Q3 FY26, while revenue moderated slightly from ₹1,876.3 crore in the previous quarter.
Total expenses increased to ₹1,730.94 crore in Q4 FY26 compared to ₹1,591.22 crore in the same period last year, as reported by the company. Employee benefit expenses stood at ₹438.9 crore during the quarter compared with ₹393.6 crore a year ago, while other expenses also increased to ₹648.7 crore from ₹573.5 crore. Despite higher costs, the company maintained healthy pre-R&D operating margins while delivering revenue growth across key segments. The growth was supported by disciplined execution across businesses and continued focus on profitability and operational delivery.
The quarterly performance reflected stronger profitability despite higher operating expenses, aided by significant deferred tax benefits. Deferred tax adjustments contributed a credit of ₹114.2 crore in Q4 FY26 against a deferred tax expense of ₹2.1 crore in Q3 FY26. The company reassessed recoverability of deferred tax assets and tax credits following amendments in the Finance Act, resulting in recognition of deferred tax assets aggregating ₹100.3 crore. However, the quarter also included exceptional charges related to labour code implementation and the Sikkim manufacturing facility. Alembic recognised an incremental labour-code-related impact of ₹6.4 crore for the quarter and ₹48.6 crore for the full year, along with a ₹18.4 crore write-down relating to assets classified as held for sale at its Sikkim facility.
For the full fiscal year FY26, consolidated net profit reached ₹674.8 crore compared to ₹583.4 crore in FY25, according to the company's filing. Consolidated revenue from operations for FY26 stood at ₹7,344.9 crore versus ₹6,672.1 crore in FY25, representing a 10.1% increase for the full year. Earnings per share for FY26 stood at ₹34.33 against ₹29.68 in FY25. The board has recommended a dividend of ₹12 per share of face value ₹2 each for the fiscal year ended March 31, 2026, compared with ₹11 per share in the previous financial year.
